Since it was founded in 2008, CureFAKtor Pharmaceuticals LLC remained under the radar until recent orphan designation for lead product CFAK-C4 in pancreatic cancer – not to mention some impressive preclinical data at the ASCO Gastrointestinal Cancers Symposium last month – put the firm on the map.